Mercedes Tkach

Head of Immunology Egle Therapeutics

Seminars

Thursday 25th March 2027
Advancing IL-2 Agonist Therapies to Expand Endogenous Tregs Across Autoimmune Diseases
11:00 am
  • Comparing IL-2 agonists with cell-based Treg therapies to understand how different approaches may address unmet needs across autoimmune diseases
  • Highlighting preclinical and translational findings to support indication selection and guide future clinical development
  • Optimizing trial design, biomarker strategies, and patient selection to demonstrate differentiation and strengthen partnering opportunities
Mercedes